Vericiguat for Heart Failure in Children

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Recruiting Phase 2 Phase 3 Interventional Study
Heart Failure Left Ventricular Systolic Dysfunction
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
29 Days – 17
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
342 (estimated)
Sponsor
Merck Sharp & Dohme LLC · Industry
Who this trial is looking for

This trial is looking for children and adolescents with heart failure caused by left ventricular problems. Participants will take vericiguat or a placebo for 16 weeks to see how it affects their health.

Are You a Good Fit for This Trial?
Rules you out Single ventricle heart diseaseSevere pulmonary hypertensionActive myocarditisSevere chronic kidney disease

You may be able to join if

  • I have chronic heart failure due to left ventricular dysfunction.
  • I weigh at least 3 kg.
  • I am between 28 days and under 18 years old.
  • I have a left ventricular ejection fraction of less than 45%.
  • I have stable medical treatment for heart failure.
  • If female, I am not pregnant or breastfeeding and use effective birth control.

You may not be able to join if

  • I am clinically unstable or have symptomatic hypotension.
  • I have a known allergy to vericiguat or similar medications.
  • I have had heart surgery or have a heart transplant.
  • I have active myocarditis.
  • I have severe chronic kidney disease.
  • I have severe pulmonary hypertension.
  • I have ongoing significant bone disease.
  • I received a COVID-19 vaccination within a week before the trial starts.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Has symptomatic chronic heart failure (HF) resulting from systemic left ventricular (LV) systolic dysfunction. * Has biventricular physiology with a morphologic systemic left ventricle. * Is currently receiving stable medical therapy for HF. * Has left ventricular ejection fra…
Contacts

Toll Free Number

1-888-577-8839

Trialsites@msd.com

CONTACT